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Background
Adoptive cell therapy with T cells bearing mutation speci-
fic T cell receptors (TCR) can be an effective method for
treating metastatic cancers. The objective of this study was
to identify mutation reactive T cells in the circulation of
patients with different types of metastatic cancer.
Methods
The strategy utilized whole exome sequencing data to
identify somatic non-synonymous mutations and then in-
silico algorithms to predict minimal epitopes encoding
mutated amino acids for each patient specific HLA-allele.
CD8-enriched PBL from each patient were stained with
tetramers generated in house by a UV-exchangeable tech-
nique as previously described for A*02:01, A*03:01,
A*11:01, B*07:02, and a commercial tetramer was acquired
for B*57:01. Based on the initial staining frequency (+tetra-
mer+ T cells recognizing 7 unique neo-antigens from the
PBL of 4 patients (ranging from 1 to 4 per patient). We
enriched the frequencies of CD8+tetramer+ cells from 0.5
to >85%, 0.3 to >65% and 0.01 to 3% from the PBL of
patients with colorectal (3971-A*02:01), lung (4014-
B*57:01), and ovarian (4067-B*07:02) cancers respectively,
using individual tetramers. Populations reactive with three
HLA-A*11:0-restricted and one HLA-A*03:01-restricted
neoantigens were also isolated from the PBL of lung can-
cer patients 4014 and 4037, respectively, using a pooled
tetramer approach.
Results
Overall, the isolated T cells recognized mutated epitopes
when co-cultured with autologous CD14+ monocytes
pulsed with mutated peptides in the context of appropriate
MHC-I alleles including HLA-A*02:01, HLA-A*03:01,
HLA-A*11:01, HLA-B*07:02, and HLA-B*57:01, with reac-
tivity detected using IFN-g ELISA. Using single cell PCR,
we could clone the TCRs reactive with an HLA-*02:01-
presented colon cancer neoantigen and an HLA-B*57:01-
presented lung cancer neoantigen. Evaluation of PBL
retrovirally-transduced with these TCRs demonstrated
that they bound to tetramers and secreted IFN-g when co-
cultured with CD14+ monocytes pulsed with appropriate
mutated peptides.
Conclusions
To conclude, tetramers offer a sensitive, fast and reliable
methodology to isolate mutation specific tumor reactive
T cells from PBL of cancer patients. Furthermore, this
method facilitates the identification, and cloning of muta-
tion reactive TCR with which to construct receptor-
engineered T cells for adoptive T cell therapy.
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